UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event De reported)		December 22, 2011	
reported)			
	NEOPROBE CORPORATION		
(Exa	ct name of registrant as specified in its char	ter)	
Delaware	0-26520	31-1080091	
(State or other jurisdiction	(Commission	(IRS Employer	
of incorporation)	File Number)	Identification No.)	
425 Metro Place North, Suite 300, Columbus, Ohio		43017	
(Address of principal executive offices)		(Zip Code)	
Registrant's telephone number, including area code (614) 793-7500		614) 793-7500	
(Former n	ame or former address, if changed since last	t report.)	
Check the appropriate box below if the Form 8-K the following provisions (see General Instruction		the filing obligation of the registrant under any of	
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

Item 8.01. Other Events.

Neoprobe Corporation (the "Company") announced on September 19, 2011, that Brent L. Larson, Senior Vice President, Chief Financial Officer; Treasurer and Secretary of the Company, Rodger A. Brown, Vice President, Regulatory Affairs and Quality Assurance of the Company, and, David C. Bupp, a member of the Company' board of directors and the Company's former President and Chief Executive Officer, each had adopted a Rule 10b5-1 sales plan (each, a "Plan" and collectively, the "Plans"). On December 22, 2011 each of Messrs Larson, Brown and Bupp advised the Company that he had terminated his Plan. Prior to termination of the Plans, Mr. Larson had sold 12,500 shares of the Company's common stock under his Plan, Mr. Brown had sold 28,715 shares under his Plan and Mr. Bupp had sold 150,000 shares under his Plan.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements contained or incorporated by reference in this Current Report on Form 8-K, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: December 22, 2011 By: /s/ Brent L. Larson

Brent L. Larson, Senior Vice President and Chief Financial Officer